Macromolecule-Linked Topoisomerase I Inhibitor for Toxicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topoisomerase I inhibitor treatments for cancer face challenges with inappropriate pharmacokinetics and toxicity, particularly in subjects with genetic defects in DNA damage response (DDR), and existing combinations with DDR or cell cycle checkpoint inhibitors do not consistently achieve effective and tolerable results.
Innovation Solution
Administering topoisomerase I inhibitors linked to a macromolecule through a beta elimination mechanism, which allows for controlled pharmacokinetics and reduced toxicity, either alone or in combination with DDR or cell cycle checkpoint inhibitors, to exploit synthetic lethal interactions in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topoisomerase I inhibitors are administered to treat cancer, then anticancer efficacy is improved, but toxicity increases and pharmacokinetics become inappropriate
Solution Approach 1:
A macromolecule carrier (such as PEG or other biocompatible polymers) is used as an intermediary to deliver the topoisomerase I inhibitor to the target. The carrier protects the drug from premature metabolism, controls its release, and improves its solubility and pharmacokinetic profile, thereby reducing toxicity while maintaining or enhancing anticancer efficacy
Solution Approach 2:
The pharmacokinetic parameters of the topoisomerase I inhibitor are modified by conjugating it to a macromolecule. This changes the drug's molecular weight, solubility, plasma half-life, and tissue distribution, optimizing its pharmacokinetic profile to achieve therapeutic efficacy at lower doses and reduce toxic side effects
2Reliability
If topoisomerase I inhibitors are combined with DDR or cell cycle checkpoint inhibitors, then synthetic lethal interactions enhance anticancer efficacy, but synergistic toxicity increases
Solution Approach 1:
The macromolecule carrier enables partial delivery of the topoisomerase I inhibitor, controlling the rate and extent of drug release. This allows the therapeutic effect to be achieved while limiting the peak concentration and duration of exposure, thereby reducing synergistic toxicity when combined with DDR or cell cycle checkpoint inhibitors
Solution Approach 2:
The conjugate system provides periodic or sustained release of the topoisomerase I inhibitor, creating oscillating drug concentrations that maintain therapeutic efficacy while allowing tissue recovery periods, thus mitigating cumulative toxic effects when used in combination therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides more effective and tolerable cancer treatments by adjusting pharmacokinetics and mitigating synergistic toxicity, with enhanced efficacy in subjects with DDR defects or when combined with additional inhibitors, as demonstrated by synergistic effects in preclinical models.
Implementation Method 1
topoisomerase I inhibitors linked to a macromolecule through a linkage that undergoes beta elimination
Data Source
AI summary
Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.